SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer

Among men, prostate cancer is the second leading cause of cancer-associated mortality, with advanced disease remaining a major clinical challenge. We describe a small molecule, SU086, as a therapeutic strategy for advanced prostate cancer. We demonstrate that SU086 inhibits the growth of prostate ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Rice, Meghan A., Kumar, Vineet, Tailor, Dhanir, Garcia-Marques, Fernando Jose, Hsu, En-Chi, Liu, Shiqin, Bermudez, Abel, Kanchustambham, Vijayalakshmi, Shankar, Vishnu, Inde, Zintis, Alabi, Busola Ruth, Muruganantham, Arvind, Shen, Michelle, Pandrala, Mallesh, Nolley, Rosalie, Aslan, Merve, Ghoochani, Ali, Agarwal, Arushi, Buckup, Mark, Kumar, Manoj, Going, Catherine C., Peehl, Donna M., Dixon, Scott J., Zare, Richard N., Brooks, James D., Pitteri, Sharon J., Malhotra, Sanjay V., Stoyanova, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861828/
https://www.ncbi.nlm.nih.gov/pubmed/35243415
http://dx.doi.org/10.1016/j.xcrm.2021.100502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861828/
https://www.ncbi.nlm.nih.gov/pubmed/35243415
http://dx.doi.org/10.1016/j.xcrm.2021.100502

Ejemplares similares